{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:02:31Z","timestamp":1792515751500,"version":"4.5.0"},"reference-count":93,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.suronc.2018.07.015","type":"journal-article","created":{"date-parts":[[2018,7,30]],"date-time":"2018-07-30T12:52:28Z","timestamp":1532955148000},"page":"611-618","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["Histone deacetylase inhibitors in hepatocellular carcinoma: A therapeutic perspective"],"prefix":"10.1016","volume":"27","author":[{"given":"Diamantis I.","family":"Tsilimigras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Ntanasis-Stathopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demetrios","family":"Moris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4451-8074","authenticated-orcid":false,"given":"Eleftherios","family":"Spartalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy M.","family":"Pawlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.suronc.2018.07.015_bib1","series-title":"GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]","author":"Ferlay","year":"2013"},{"key":"10.1016\/j.suronc.2018.07.015_bib2","series-title":"Continuous Update Project Report: Diet, Nutrition, Physical Activity and Liver Cancer","author":"World Cancer Research Fund International\/American Institute for Cancer Research","year":"2015"},{"issue":"2","key":"10.1016\/j.suronc.2018.07.015_bib3","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.suronc.2016.03.002","article-title":"Hepatocellular carcinoma: from diagnosis to treatment","volume":"25","author":"Grandhi","year":"2016","journal-title":"Surg Oncol"},{"issue":"4","key":"10.1016\/j.suronc.2018.07.015_bib4","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"49","key":"10.1016\/j.suronc.2018.07.015_bib5","article-title":"Short-term and long-term efficacy of 7 targeted therapies for the treatment of advanced hepatocellular carcinoma: a network meta-analysis: efficacy of 7 targeted therapies for AHCC","volume":"95","author":"Niu","year":"2016","journal-title":"Medicine (Baltim.)"},{"issue":"12","key":"10.1016\/j.suronc.2018.07.015_bib6","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1517\/14728222.2015.1071354","article-title":"Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?","volume":"19","author":"Gnoni","year":"2015","journal-title":"Expert Opin. Ther. Targets"},{"issue":"2","key":"10.1016\/j.suronc.2018.07.015_bib7","first-page":"133","article-title":"Epigenetic regulation on gene expression induced by physical exercise","volume":"13","author":"Ntanasis-Stathopoulos","year":"2013","journal-title":"J. Musculoskelet. Neuronal Interact."},{"issue":"2","key":"10.1016\/j.suronc.2018.07.015_bib8","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/hepr.12757","article-title":"Histone deacetylases function as novel potential therapeutic targets for cancer","volume":"47","author":"Zhang","year":"2017","journal-title":"Hepatol. Res."},{"issue":"1\u20132","key":"10.1016\/j.suronc.2018.07.015_bib9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1615\/CritRevOncog.2015012997","article-title":"Histone deacetylases and mechanisms of regulation of gene expression","volume":"20","author":"Chen","year":"2015","journal-title":"Crit. Rev. Oncog."},{"issue":"1","key":"10.1016\/j.suronc.2018.07.015_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4068\/cmj.2016.52.1.1","article-title":"HDAC and HDAC inhibitor: from cancer to cardiovascular diseases","volume":"52","author":"Yoon","year":"2016","journal-title":"Chonnam Med J"},{"issue":"5","key":"10.1016\/j.suronc.2018.07.015_bib11","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.suronc.2018.07.015_bib12","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s13238-014-0065-9","article-title":"The genetic and epigenetic alterations in human hepatocellular carcinoma: a recent update","volume":"5","author":"Liu","year":"2014","journal-title":"Protein Cell"},{"issue":"4","key":"10.1016\/j.suronc.2018.07.015_bib13","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/hep.20878","article-title":"Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling","volume":"42","author":"Nam","year":"2005","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.suronc.2018.07.015_bib14","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1053\/j.gastro.2012.05.033","article-title":"Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells","volume":"143","author":"Buurman","year":"2012","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.suronc.2018.07.015_bib15","doi-asserted-by":"crossref","first-page":"e34265","DOI":"10.1371\/journal.pone.0034265","article-title":"HDAC1 inactivation induces mitotic defect and caspase-independent autophagic cell death in liver cancer","volume":"7","author":"Xie","year":"2012","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.suronc.2018.07.015_bib16","doi-asserted-by":"crossref","first-page":"e28103","DOI":"10.1371\/journal.pone.0028103","article-title":"Aberrant regulation of HDAC2 mediates proliferation of hepatocellular carcinoma cells by deregulating expression of G1\/S cell cycle proteins","volume":"6","author":"Noh","year":"2011","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.suronc.2018.07.015_bib17","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1158\/0008-5472.CAN-13-2109","article-title":"HDAC2 provides a critical support to malignant progression of hepatocellular carcinoma through feedback control of mTORC1 and AKT","volume":"74","author":"Noh","year":"2014","journal-title":"Canc. Res."},{"issue":"12","key":"10.1016\/j.suronc.2018.07.015_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0014460","article-title":"Identification of histone deacetylase 3 as a biomarker for tumor recurrence following liver transplantation in HBV-associated hepatocellular carcinoma","volume":"5","author":"Wu","year":"2010","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.suronc.2018.07.015_bib19","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1007\/s10620-013-2867-7","article-title":"The up-regulation of histone deacetylase 8 promotes proliferation and inhibits apoptosis in hepatocellular carcinoma","volume":"58","author":"Wu","year":"2013","journal-title":"Dig. Dis. Sci."},{"issue":"13","key":"10.1016\/j.suronc.2018.07.015_bib20","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1158\/0008-5472.CAN-07-6655","article-title":"Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis","volume":"68","author":"Datta","year":"2008","journal-title":"Canc. Res."},{"issue":"11","key":"10.1016\/j.suronc.2018.07.015_bib21","doi-asserted-by":"crossref","first-page":"11523","DOI":"10.1007\/s13277-014-2358-2","article-title":"Down-regulation of HDAC5 inhibits growth of human hepatocellular carcinoma by induction of apoptosis and cell cycle arrest","volume":"35","author":"Fan","year":"2014","journal-title":"Tumour Biol"},{"issue":"6","key":"10.1016\/j.suronc.2018.07.015_bib22","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/hep.24606","article-title":"The histone deacetylase 4\/SP1\/microrna-200a regulatory network contributes to aberrant histone acetylation in hepatocellular carcinoma","volume":"54","author":"Yuan","year":"2011","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.suronc.2018.07.015_bib23","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1159\/000369733","article-title":"MiR-376a and histone deacetylation 9 form a regulatory circuitry in hepatocellular carcinoma","volume":"35","author":"Zheng","year":"2015","journal-title":"Cell. Physiol. Biochem."},{"issue":"3","key":"10.1016\/j.suronc.2018.07.015_bib24","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.bbrc.2007.09.026","article-title":"HDAC10 promoter polymorphism associated with development of HCC among chronic HBV patients","volume":"363","author":"Park","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.suronc.2018.07.015_bib25","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/hep.25699","article-title":"Histone deacetylase 6 functions as a tumor suppressor by activating c-Jun NH2-terminal kinase-mediated beclin 1-dependent autophagic cell death in liver cancer","volume":"56","author":"Jung","year":"2012","journal-title":"Hepatology"},{"issue":"20","key":"10.1016\/j.suronc.2018.07.015_bib26","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1038\/onc.2013.216","article-title":"MicroRNA-29c functions as a tumor suppressor by direct targeting oncogenic SIRT1 in hepatocellular carcinoma","volume":"33","author":"Bae","year":"2014","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.suronc.2018.07.015_bib27","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/hep.26101","article-title":"Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b","volume":"57","author":"Kim","year":"2013","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.suronc.2018.07.015_bib28","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/hep.26278","article-title":"SIRT2 overexpression in hepatocellular carcinoma mediates epithelial to mesenchymal transition by protein kinase B\/glycogen synthase kinase-3beta\/beta-catenin signaling","volume":"57","author":"Chen","year":"2013","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.suronc.2018.07.015_bib29","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/hep.26413","article-title":"Sirtuin-6-dependent genetic and epigenetic alterations are associated with poor clinical outcome in hepatocellular carcinoma patients","volume":"58","author":"Marquardt","year":"2013","journal-title":"Hepatology"},{"issue":"13","key":"10.1016\/j.suronc.2018.07.015_bib30","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1158\/1078-0432.CCR-15-1638","article-title":"SIRT6 overexpression potentiates apoptosis evasion in hepatocellular carcinoma via BCL2-associated X protein-dependent apoptotic pathway","volume":"22","author":"Ran","year":"2016","journal-title":"Clin. Canc. Res."},{"issue":"2","key":"10.1016\/j.suronc.2018.07.015_bib31","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00428-011-1103-0","article-title":"Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC","volume":"459","author":"Quint","year":"2011","journal-title":"Virchows Arch."},{"issue":"5","key":"10.1016\/j.suronc.2018.07.015_bib32","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.3892\/or.2015.4263","article-title":"HDAC1 and HDAC2 independently predict mortality in hepatocellular carcinoma by a competing risk regression model in a Southeast Asian population","volume":"34","author":"Ler","year":"2015","journal-title":"Oncol. Rep."},{"issue":"9","key":"10.1016\/j.suronc.2018.07.015_bib33","doi-asserted-by":"crossref","first-page":"e45119","DOI":"10.1371\/journal.pone.0045119","article-title":"SIRT1 and c-Myc promote liver tumor cell survival and predict poor survival of human hepatocellular carcinomas","volume":"7","author":"Jang","year":"2012","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.suronc.2018.07.015_bib34","doi-asserted-by":"crossref","first-page":"e51703","DOI":"10.1371\/journal.pone.0051703","article-title":"Low SIRT3 expression correlates with poor differentiation and unfavorable prognosis in primary hepatocellular carcinoma","volume":"7","author":"Zhang","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.suronc.2018.07.015_bib35","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/1471-2407-14-297","article-title":"Down-regulation of sirtuin 3 is associated with poor prognosis in hepatocellular carcinoma after resection","volume":"14","author":"Wang","year":"2014","journal-title":"BMC Canc."},{"issue":"3","key":"10.1016\/j.suronc.2018.07.015_bib36","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/hep.21054","article-title":"HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL","volume":"43","author":"Pathil","year":"2006","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.suronc.2018.07.015_bib37","doi-asserted-by":"crossref","first-page":"881","DOI":"10.3892\/ol.2014.2739","article-title":"Activation of the intrinsic apoptosis pathway contributes to the induction of apoptosis in hepatocellular carcinoma cells by valproic acid","volume":"9","author":"Yang","year":"2015","journal-title":"Oncol Lett"},{"issue":"10","key":"10.1016\/j.suronc.2018.07.015_bib38","doi-asserted-by":"crossref","first-page":"996","DOI":"10.7150\/jca.12135","article-title":"The histone deacetylase inhibitor vaproic acid induces cell growth arrest in hepatocellular carcinoma cells via suppressing Notch signaling","volume":"6","author":"Sun","year":"2015","journal-title":"J. Canc."},{"issue":"14","key":"10.1016\/j.suronc.2018.07.015_bib39","doi-asserted-by":"crossref","first-page":"6321","DOI":"10.1158\/0008-5472.CAN-04-4252","article-title":"Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate","volume":"65","author":"Armeanu","year":"2005","journal-title":"Canc. Res."},{"key":"10.1016\/j.suronc.2018.07.015_bib40","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1186\/1471-2407-12-386","article-title":"Inhibition of DNA methyltransferase activity and expression by treatment with the pan-deacetylase inhibitor panobinostat in hepatocellular carcinoma cell lines","volume":"12","author":"Zopf","year":"2012","journal-title":"BMC Canc."},{"issue":"15","key":"10.1016\/j.suronc.2018.07.015_bib41","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1016\/j.yexcr.2012.04.018","article-title":"Downregulation of HMGA2 by the pan-deacetylase inhibitor panobinostat is dependent on hsa-let-7b expression in liver cancer cell lines","volume":"318","author":"Di Fazio","year":"2012","journal-title":"Exp. Cell Res."},{"issue":"8","key":"10.1016\/j.suronc.2018.07.015_bib42","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/mc.22122","article-title":"The pan-deacetylase inhibitor panobinostat suppresses the expression of oncogenic miRNAs in hepatocellular carcinoma cell lines","volume":"54","author":"Henrici","year":"2015","journal-title":"Mol. Carcinog."},{"issue":"4","key":"10.1016\/j.suronc.2018.07.015_bib43","first-page":"285","article-title":"The pan-deacetylase inhibitor panobinostat inhibits growth of hepatocellular carcinoma models by alternative pathways of apoptosis","volume":"32","author":"Di Fazio","year":"2010","journal-title":"Cell. Oncol."},{"issue":"2","key":"10.1016\/j.suronc.2018.07.015_bib44","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1593\/tlo.12271","article-title":"Endoplasmic reticulum stress plays a pivotal role in cell death mediated by the pan-deacetylase inhibitor panobinostat in human hepatocellular cancer cells","volume":"6","author":"Montalbano","year":"2013","journal-title":"Transl Oncol"},{"issue":"20","key":"10.1016\/j.suronc.2018.07.015_bib45","doi-asserted-by":"crossref","first-page":"28998","DOI":"10.18632\/oncotarget.8585","article-title":"Autophagy-related cell death by pan-histone deacetylase inhibition in liver cancer","volume":"7","author":"Di Fazio","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.suronc.2018.07.015_bib46","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3892\/ijo.2015.3087","article-title":"The pan-deacetylase inhibitor panobinostat affects angiogenesis in hepatocellular carcinoma models via modulation of CTGF expression","volume":"47","author":"Gahr","year":"2015","journal-title":"Int. J. Oncol."},{"issue":"1","key":"10.1016\/j.suronc.2018.07.015_bib47","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/1476-4598-12-114","article-title":"LBH589 Inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin\/STAT3\/Akt pathway","volume":"12","author":"Song","year":"2013","journal-title":"Mol. Canc."},{"issue":"2","key":"10.1016\/j.suronc.2018.07.015_bib48","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0168-8278(01)00257-4","article-title":"The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells","volume":"36","author":"Herold","year":"2002","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.suronc.2018.07.015_bib49","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/ijc.10699","article-title":"Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest\/apoptosis and hepatocyte differentiation in human hepatoma cells","volume":"103","author":"Yamashita","year":"2003","journal-title":"Int. J. Canc."},{"issue":"2","key":"10.1016\/j.suronc.2018.07.015_bib50","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.bbrc.2006.12.222","article-title":"p21waf1\/Cip1 partially mediates apoptosis in hepatocellular carcinoma cells","volume":"354","author":"Svechnikova","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.suronc.2018.07.015_bib51","doi-asserted-by":"crossref","first-page":"322","DOI":"10.4161\/cc.11.2.18758","article-title":"Interaction between ZBP-89 and p53 mutants and its contribution to effects of HDACi on hepatocellular carcinoma","volume":"11","author":"Zhang","year":"2012","journal-title":"Cell Cycle"},{"issue":"1","key":"10.1016\/j.suronc.2018.07.015_bib52","first-page":"177","article-title":"Histone deacetylase inhibitors induce in human hepatoma HepG2 cells acetylation of p53 and histones in correlation with apoptotic effects","volume":"32","author":"Carlisi","year":"2008","journal-title":"Int. J. Oncol."},{"issue":"12","key":"10.1016\/j.suronc.2018.07.015_bib53","first-page":"5263","article-title":"Antitumoral efficacy of four histone deacetylase inhibitors in hepatoma in vitro and in vivo","volume":"32","author":"Ganslmayer","year":"2012","journal-title":"Anticancer Res."},{"issue":"9","key":"10.1016\/j.suronc.2018.07.015_bib54","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.molimm.2004.05.005","article-title":"Histone-deacetylase inhibitors induce the cathelicidin LL-37 in gastrointestinal cells","volume":"41","author":"Schauber","year":"2004","journal-title":"Mol. Immunol."},{"issue":"10","key":"10.1016\/j.suronc.2018.07.015_bib55","doi-asserted-by":"crossref","first-page":"655","DOI":"10.5483\/BMBRep.2009.42.10.655","article-title":"Anti-invasive activity of histone deacetylase inhibitors via the induction of Egr-1 and the modulation of tight junction-related proteins in human hepatocarcinoma cells","volume":"42","author":"Kim","year":"2009","journal-title":"BMB Rep"},{"issue":"31","key":"10.1016\/j.suronc.2018.07.015_bib56","doi-asserted-by":"crossref","first-page":"5159","DOI":"10.3748\/wjg.v19.i31.5159","article-title":"Effects of SAHA on proliferation and apoptosis of hepatocellular carcinoma cells and hepatitis B virus replication","volume":"19","author":"Wang","year":"2013","journal-title":"World J. Gastroenterol."},{"issue":"8","key":"10.1016\/j.suronc.2018.07.015_bib57","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.4161\/auto.6.8.13365","article-title":"Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma","volume":"6","author":"Liu","year":"2010","journal-title":"Autophagy"},{"issue":"9","key":"10.1016\/j.suronc.2018.07.015_bib58","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/jcb.24541","article-title":"Suppressive effect of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) on hepatitis C virus replication","volume":"114","author":"Sato","year":"2013","journal-title":"J. Cell. Biochem."},{"issue":"1","key":"10.1016\/j.suronc.2018.07.015_bib59","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/bjc.2014.547","article-title":"Histone deacetylase inhibitor SAHA epigenetically regulates miR-17-92 cluster and MCM7 to upregulate MICA expression in hepatoma","volume":"112","author":"Yang","year":"2015","journal-title":"Br. J. Canc."},{"issue":"8","key":"10.1016\/j.suronc.2018.07.015_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106224","article-title":"The histone deacetylase inhibitor, Vorinostat, represses hypoxia inducible factor 1 alpha expression through translational inhibition","volume":"9","author":"Hutt","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.suronc.2018.07.015_bib61","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/hep.23964","article-title":"Novel mechanism by which histone deacetylase inhibitors facilitate topoisomerase IIalpha degradation in hepatocellular carcinoma cells","volume":"53","author":"Chen","year":"2011","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.suronc.2018.07.015_bib62","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s10637-014-0188-0","article-title":"4,5-Diaryl imidazoles with hydroxamic acid appendages as anti-hepatoma agents","volume":"33","author":"Di Fazio","year":"2015","journal-title":"Invest. N. Drugs"},{"issue":"11","key":"10.1016\/j.suronc.2018.07.015_bib63","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s10495-016-1278-6","article-title":"Novel SAHA analogues inhibit HDACs, induce apoptosis and modulate the expression of microRNAs in hepatocellular carcinoma","volume":"21","author":"Srinivas","year":"2016","journal-title":"Apoptosis"},{"issue":"5","key":"10.1016\/j.suronc.2018.07.015_bib64","doi-asserted-by":"crossref","first-page":"6235","DOI":"10.1007\/s11033-011-1443-5","article-title":"Dual effects of sodium butyrate on hepatocellular carcinoma cells","volume":"39","author":"Jiang","year":"2012","journal-title":"Mol. Biol. Rep."},{"issue":"1","key":"10.1016\/j.suronc.2018.07.015_bib65","first-page":"233","article-title":"Gene expression associated with the decrease in malignant phenotype of human liver cancer cells following stimulation with a histone deacetylase inhibitor","volume":"26","author":"Wakabayashi","year":"2005","journal-title":"Int. J. Oncol."},{"issue":"2","key":"10.1016\/j.suronc.2018.07.015_bib66","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10637-009-9219-7","article-title":"The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines","volume":"28","author":"Ma","year":"2010","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.suronc.2018.07.015_bib67","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.bcp.2016.12.008","article-title":"Romidepsin induces G2\/M phase arrest via Erk\/cdc25C\/cdc2\/cyclinB pathway and apoptosis induction through JNK\/c-Jun\/caspase3 pathway in hepatocellular carcinoma cells","volume":"127","author":"Sun","year":"2017","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.suronc.2018.07.015_bib68","doi-asserted-by":"crossref","first-page":"402","DOI":"10.18632\/oncotarget.6352","article-title":"Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.suronc.2018.07.015_bib69","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/hep.21804","article-title":"Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma","volume":"46","author":"Lu","year":"2007","journal-title":"Hepatology"},{"issue":"14","key":"10.1016\/j.suronc.2018.07.015_bib70","doi-asserted-by":"crossref","first-page":"4822","DOI":"10.1158\/1078-0432.CCR-04-0349","article-title":"Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But","volume":"10","author":"Coradini","year":"2004","journal-title":"Clin. Canc. Res."},{"issue":"6","key":"10.1016\/j.suronc.2018.07.015_bib71","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00432-004-0664-6","article-title":"The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells","volume":"131","author":"Ocker","year":"2005","journal-title":"J. Canc. Res. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.suronc.2018.07.015_bib72","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.bbrc.2013.05.088","article-title":"Synergistically killing activity of aspirin and histone deacetylase inhibitor valproic acid (VPA) on hepatocellular cancer cells","volume":"436","author":"Li","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"3","key":"10.1016\/j.suronc.2018.07.015_bib73","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/hep.24101","article-title":"Enrichment of Nur77 mediated by retinoic acid receptor beta leads to apoptosis of human hepatocellular carcinoma cells induced by fenretinide and histone deacetylase inhibitors","volume":"53","author":"Yang","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.suronc.2018.07.015_bib74","doi-asserted-by":"crossref","DOI":"10.1038\/mto.2015.19","article-title":"Combination of the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus as a new option for epi-virotherapeutic treatment of hepatocellular carcinoma","volume":"2","author":"Ruf","year":"2015","journal-title":"Mol Ther Oncolytics"},{"issue":"2","key":"10.1016\/j.suronc.2018.07.015_bib75","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.1016\/j.ijrobp.2011.12.022","article-title":"Radiosensitizing effect of a phenylbutyrate-derived histone deacetylase inhibitor in hepatocellular carcinoma","volume":"83","author":"Lu","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"17","key":"10.1016\/j.suronc.2018.07.015_bib76","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.3748\/wjg.v20.i17.4953","article-title":"Inhibition of autophagy signi fi cantly enhances combination therapy with sorafenib and HDAC inhibitors for human hepatoma cells","volume":"20","author":"Yuan","year":"2014","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.suronc.2018.07.015_bib77","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3892\/ijo.2014.2423","article-title":"Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK\/NF-kappaB signaling","volume":"45","author":"Hsu","year":"2014","journal-title":"Int. J. Oncol."},{"issue":"6","key":"10.1016\/j.suronc.2018.07.015_bib78","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.jhep.2012.01.009","article-title":"Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib","volume":"56","author":"Lachenmayer","year":"2012","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.suronc.2018.07.015_bib79","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1158\/1078-0432.CCR-12-3909","article-title":"Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivo","volume":"20","author":"Chen","year":"2014","journal-title":"Clin. Canc. Res."},{"issue":"10","key":"10.1016\/j.suronc.2018.07.015_bib80","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1002\/jcp.24362","article-title":"Sorafenib and HDAC inhibitors synergize with TRAIL to kill tumor cells","volume":"228","author":"Hamed","year":"2013","journal-title":"J. Cell. Physiol."},{"issue":"6","key":"10.1016\/j.suronc.2018.07.015_bib81","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1002\/hep.25566","article-title":"Synergistic inhibition of hepatocellular carcinoma growth by cotargeting chromatin modifying enzymes and poly (ADP-ribose) polymerases","volume":"55","author":"Zhang","year":"2012","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.suronc.2018.07.015_bib82","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jhep.2015.06.009","article-title":"Defeating EpCAM(+) liver cancer stem cells by targeting chromatin remodeling enzyme CHD4 in human hepatocellular carcinoma","volume":"63","author":"Nio","year":"2015","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.suronc.2018.07.015_bib83","first-page":"1093","article-title":"Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines","volume":"31","author":"Spratlin","year":"2011","journal-title":"Anticancer Res."},{"issue":"1","key":"10.1016\/j.suronc.2018.07.015_bib84","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jhep.2011.07.013","article-title":"Dual targeting of mTORC1\/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo","volume":"56","author":"Shao","year":"2012","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.suronc.2018.07.015_bib85","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jhep.2016.02.043","article-title":"Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - the SHELTER study","volume":"65","author":"Bitzer","year":"2016","journal-title":"J. Hepatol."},{"issue":"27","key":"10.1016\/j.suronc.2018.07.015_bib86","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1200\/JCO.2011.41.2395","volume":"30","author":"Yeo","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.suronc.2018.07.015_bib87","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/ijc.31117","article-title":"Targeting class I histone deacetylases by the novel small molecule inhibitor 4SC-202 blocks oncogenic hedgehog-GLI signaling and overcomes smoothened inhibitor resistance","volume":"142","author":"Gruber","year":"2018","journal-title":"Int. J. Canc."},{"issue":"4","key":"10.1016\/j.suronc.2018.07.015_bib88","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/annonc\/mdy050","article-title":"Epigenetic modifiers as new immunomodulatory therapies in solid tumours","volume":"29","author":"Aspeslagh","year":"2018","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.suronc.2018.07.015_bib89","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/10408440590935639","article-title":"Differential effects of histone deacetylase inhibitors in tumor and normal cells-what is the toxicological relevance?","volume":"35","author":"Papeleu","year":"2005","journal-title":"Crit. Rev. Toxicol."},{"issue":"9","key":"10.1016\/j.suronc.2018.07.015_bib90","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd4360","article-title":"Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders","volume":"13","author":"Falkenberg","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.suronc.2018.07.015_bib91","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","article-title":"Cancer epigenetics: from mechanism to therapy","volume":"150","author":"Dawson","year":"2012","journal-title":"Cell"},{"issue":"20","key":"10.1016\/j.suronc.2018.07.015_bib92","doi-asserted-by":"crossref","first-page":"8903","DOI":"10.1021\/jm3011838","article-title":"Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response","volume":"55","author":"Wong","year":"2012","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.suronc.2018.07.015_bib93","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s11307-014-0774-8","article-title":"Monitoring tumor response after histone deacetylase inhibitor treatment using 3'-Deoxy-3'-[18F]-fluorothymidine PET","volume":"17","author":"Chan","year":"2015","journal-title":"Mol. Imag. Biol."}],"container-title":["Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960740418301804?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960740418301804?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T18:10:19Z","timestamp":1547057419000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960740418301804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":93,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S0960740418301804"],"URL":"https:\/\/doi.org\/10.1016\/j.suronc.2018.07.015","relation":{},"ISSN":["0960-7404"],"issn-type":[{"value":"0960-7404","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Histone deacetylase inhibitors in hepatocellular carcinoma: A therapeutic perspective","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.suronc.2018.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}